000267562 001__ 267562
000267562 005__ 20240619133941.0
000267562 0247_ $$2doi$$a10.3390/cancers15030742
000267562 0247_ $$2pmid$$apmid:36765699
000267562 0247_ $$2altmetric$$aaltmetric:143426907
000267562 037__ $$aDKFZ-2023-00340
000267562 041__ $$aEnglish
000267562 082__ $$a610
000267562 1001_ $$0P:(DE-He78)d377305c25d3762da05592bf075d1597$$aKim, Ji-Young$$b0$$eFirst author$$udkfz
000267562 245__ $$aCombined Hyperthermia and Re-Irradiation in Non-Breast Cancer Patients: A Systematic Review.
000267562 260__ $$aBasel$$bMDPI$$c2023
000267562 3367_ $$2DRIVER$$aarticle
000267562 3367_ $$2DataCite$$aOutput Types/Journal article
000267562 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718797144_31900$$xReview Article
000267562 3367_ $$2BibTeX$$aARTICLE
000267562 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000267562 3367_ $$00$$2EndNote$$aJournal Article
000267562 500__ $$a#EA:E050#LA:E050#
000267562 520__ $$aThis systematic literature review summarizes clinical studies and trials involving combined non-ablative hyperthermia and re-irradiation in locoregionally recurrent cancer except breast cancer.One database and one registry, MEDLINE and clinicaltrials.gov, respectively, were searched for studies on combined non-ablative hyperthermia and re-irradiation in non-breast cancer patients. Extracted study characteristics included treatment modalities and re-irradiation dose concepts. Outcomes of interest were tumor response, survival measures, toxicity data and palliation. Within-study bias assessment included the identification of conflict of interest (COI). The final search was performed on 29 August 2022.Twenty-three articles were included in the final analysis, reporting on 603 patients with eight major tumor types. Twelve articles (52%) were retrospective studies. Only one randomized trial was identified. No COI statement was declared in 11 studies. Four of the remaining twelve studies exhibited significant COI. Low study and patient numbers, high heterogeneity in treatment modalities and endpoints, as well as significant within- and across-study bias impeded the synthesis of results.Outside of locoregionally recurrent breast cancer, the role of combined moderate hyperthermia and re-irradiation can so far not be established. This review underscores the necessity for more clinical trials to generate higher levels of clinical evidence for combined re-irradiation and hyperthermia.
000267562 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000267562 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000267562 650_7 $$2Other$$ahyperthermia
000267562 650_7 $$2Other$$are-irradiation
000267562 7001_ $$aZschaeck, Sebastian$$b1
000267562 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b2$$udkfz
000267562 7001_ $$0P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aWeykamp, Fabian$$b3$$eLast author$$udkfz
000267562 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15030742$$gVol. 15, no. 3, p. 742 -$$n3$$p742$$tCancers$$v15$$x2072-6694$$y2023
000267562 909CO $$ooai:inrepo02.dkfz.de:267562$$pVDB
000267562 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d377305c25d3762da05592bf075d1597$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000267562 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000267562 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000267562 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000267562 9141_ $$y2023
000267562 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-24T07:56:58Z
000267562 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000267562 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000267562 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000267562 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000267562 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000267562 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000267562 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000267562 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000267562 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000267562 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000267562 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000267562 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000267562 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000267562 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000267562 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000267562 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000267562 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000267562 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000267562 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000267562 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000267562 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000267562 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000267562 980__ $$ajournal
000267562 980__ $$aVDB
000267562 980__ $$aI:(DE-He78)E050-20160331
000267562 980__ $$aI:(DE-He78)HD01-20160331
000267562 980__ $$aUNRESTRICTED